Non-Small Cell Lung Cancer
Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
Published in Physician Law Weekly, April 2nd, 2008
Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, announced that enrollment has begun in a Phase 1b study evaluating the vascular disrupting agent (VDA) NPI-2358 in combination with standard chemotherapy in patients with non-small cell lung cancer (NSCLC). This study follows on positive outcomes in a Phase 1 single-agent clinical trial assessing the safety, pharmacokinetics, pharmacodynamics (PK/PD) and efficacy of NPI-2358 in various tumor types.
The open-label Phase 1b study will assess escalating doses of NPI-2358 in combination with docetaxel in patients with NSCLC who previously failed at least one chemotherapy regimen. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2008-04-02)
More Articles from Physician Law Weekly
- Affiliated Computer Services, Inc.
ACS Awarded Contract to Provide Comprehensive Outsourcing Services for CAQH - Agilysys, Inc.
Agilysys Hosts IBM Specialist at Health Care Webinar Offering Data Storage Solutions - AHA Investment Funds
Turner Investment Partners Added to AHA Diversified Equity Fund - Allergies
NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring - Allergies
Studies from University Hospital add new findings in the area of allergies - Alliance of Catholic Health Care
Judge Tosses Lawsuit Attacking Federal ''Conscience Clause;'' Hospitals, Health Care Workers Can't Be Forced to Perform Abortions - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
